China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has entered into a long-term partnership with compatriot firm neoX Biotech, an artificial intelligence (AI) empowered company. The collaboration will focus on the process development and large-scale manufacturing of neoX’s in-house developed macromolecule drugs. Financial details of the partnership were not disclosed.
Partnership Focus and Objectives
neoX Biotech will leverage WuXi Biologics’ extensive experience and expertise to accelerate the pre-clinical pharmacy research and clinical manufacturing of macromolecules. This includes supporting the clinical filing for neoX’s first drug candidate in both the US and China. WuXi Biologics will provide comprehensive support to neoX, covering target discovery, molecular design, drug research, and clinical development.
Therapeutic Areas and Future Outlook
The partnership aims to advance the development of innovative therapies for cancer, autoimmune diseases, and rare diseases. By combining WuXi Biologics’ robust CRDMO capabilities with neoX Biotech’s AI-driven approach, the collaboration is expected to drive efficiency and innovation in the development and manufacturing of next-generation macromolecule drugs.-Fineline Info & Tech
